Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Immuron Limited (IMC.AX)
Carlton, VIC, AU
Immuron Limited, an Australian biopharmaceutical firm founded in 1994 and headquartered in Carlton, is dedicated to the exploration, advancement, and worldwide commercialization of polyclonal antibodies. Operating across two divisions—Research and Development, and Hyperimmune Products—the company serves markets in Australia, Israel, Canada, the United States, and other international regions. Its current product portfolio includes Travelan, an over-the-counter remedy aimed at reducing the likelihood of travelers' diarrhea and minor gastrointestinal complaints, which also functions as a dietary supplement for digestive well-being and gut protection. Another offering, Protectyn, is an immune supplement formulated to bolster healthy digestive function and liver support. Beyond its commercialized products, Immuron is actively progressing several pipeline candidates. Travelan (IMM-124E) is currently undergoing a Phase III registration trial in the United States for the prevention of travelers' diarrhea, alongside a Phase II field trial for the same indication, and has demonstrated antiviral efficacy against SARS-CoV-2. Concurrently, IMM-529 is in Phase I/IIa clinical trials, targeting patients with recurrent Clostridium difficile infections. The company has also established key research alliances, including an agreement with the Naval Medical Research Center to develop and clinically evaluate a therapeutic agent against Campylobacter and enterotoxigenic Escherichia coli infections, and a collaborative effort with the Walter Reed Army Institute of Research to create an oral treatment for shigellosis.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -9.09% | +29.03% | +33.33% | +42.86% | -37.50% | +11.11% | -40.30% | -52.38% | -75.00% | -87.77% | -99.42% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+48.6% ★ Q4'25: +77.6% (vs Q4'23)
-
EPS growth Biotechnology: +29.7%+25.7% Q4'25: +23.1% (vs Q4'23)
-
FCF margin FCF growth · Biotechnology: +16.2%-80.1% Q4'25: -59.3% (vs Q4'23)
-
EBIT margin Biotechnology: +0.0%-73.5% Q4'25: -55.1% (vs Q4'23)
-
ROIC Biotechnology: -16.1%-231.0% Q4'25: -245.0% (vs Q4'23)
-
Share dilution Biotechnology: -3.4%+1.4% ★ Q4'25: +20.3% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.02× Q4'25: 0.00× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Jun 2014 actual |
Jun 2015 actual |
Jun 2016 actual |
Jun 2017 actual |
Jun 2018 actual |
Jun 2019 actual |
Jun 2020 actual |
Jun 2021 actual |
Jun 2022 actual |
Jun 2023 actual |
Jun 2025 actual |
Jun 2026 1 Rev. Ana. 1 EPS Ana. |
Jun 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
981.1K
est: 1.32M (-25.6%)
|
1.00M
est: 2.20M (-54.4%)
|
1.00M
est: 2.00M (-49.9%)
|
1.40M
est: 1.40M (+0.0%)
|
1.84M
est: 2.20M (-16.2%)
|
2.39M
est: 2.00M (+19.4%)
|
2.52M
est: 1.40M (+80.4%)
|
145.8K
est: 2.01M (-92.7%)
|
765.2K
est: 500.0K (+53.0%)
|
1.80M
est: 5.00M (-63.9%)
|
7.29M
est: 7.30M (-0.2%)
|
8.02M
8.02M – 8.02M
+9.8% YoY
|
8.98M
8.98M – 8.98M
+12.0% YoY
|
| EBITDA |
-2.15M
est: -1.25M (-72.4%)
|
-4.28M
est: -2.08M (-105.7%)
|
-8.26M
est: -1.89M (-336.9%)
|
-8.35M
est: -1.32M (-532.4%)
|
-3.24M
est: -4.96M (+34.6%)
|
-4.70M
est: -1.89M (-148.7%)
|
-3.17M
est: -1.32M (-140.1%)
|
-8.33M
est: -1.90M (-338.3%)
|
-3.08M
est: -472.8K (-551.2%)
|
-3.80M
est: -4.73M (+19.7%)
|
-5.31M
est: -6.90M (+23.1%)
|
-7.58M
-7.58M – -7.58M
-9.8% YoY
|
-8.49M
-8.49M – -8.49M
-12.0% YoY
|
| EBIT |
-2.62M
est: -1.25M (-109.7%)
|
-4.17M
est: -2.08M (-100.2%)
|
-8.24M
est: -1.89M (-335.0%)
|
-8.35M
est: -1.32M (-531.9%)
|
-3.25M
est: -4.96M (+34.5%)
|
-4.71M
est: -1.89M (-148.6%)
|
-2.91M
est: -1.32M (-119.7%)
|
-8.37M
est: -1.90M (-340.0%)
|
-3.11M
est: -473.5K (-555.9%)
|
-3.85M
est: -4.74M (+18.8%)
|
-5.36M
est: -6.91M (+22.5%)
|
-7.59M
-7.59M – -7.59M
-9.8% YoY
|
-8.50M
-8.50M – -8.50M
-12.0% YoY
|
| Net Income |
-2.50M
est: -9.25M (+73.0%)
|
-2.69M
est: -9.16M (+70.6%)
|
-7.07M
est: -11.44M (+38.2%)
|
-6.80M
est: -36.95M (+81.6%)
|
-3.01M
est: -4.96M (+39.3%)
|
-4.66M
est: -11.44M (+59.3%)
|
-2.93M
est: -36.95M (+92.1%)
|
-8.38M
est: -20.78M (+59.7%)
|
-2.85M
est: -21.36M (+86.6%)
|
-3.79M
est: -17.32M (+78.1%)
|
-5.22M
est: -230.9K (-2,158.6%)
|
-68.8K
-68.8K – -68.8K
+70.2% YoY
|
-87.3K
-87.3K – -87.3K
-26.8% YoY
|
| SGA |
886.4K
est: 14.30M (-93.8%)
|
1.91M
est: 23.84M (-92.0%)
|
5.33M
est: 21.68M (-75.4%)
|
4.38M
est: 15.13M (-71.1%)
|
4.07M
est: 23.84M (-82.9%)
|
5.81M
est: 21.68M (-73.2%)
|
3.97M
est: 15.13M (-73.7%)
|
6.38M
est: 21.77M (-70.7%)
|
3.92M
est: 5.42M (-27.6%)
|
5.15M
est: 54.19M (-90.5%)
|
7.94M
est: 79.12M (-90.0%)
|
86.87M
86.87M – 86.87M
+9.8% YoY
|
97.30M
97.30M – 97.30M
+12.0% YoY
|
| EPS |
-0.06
est: -0.04 (-48.6%)
|
-0.04
est: -0.04 (+9.4%)
|
-0.09
est: -0.05 (-86.7%)
|
-0.06
est: -0.16 (+59.8%)
|
-0.02
est: -0.04 (+43.2%)
|
-0.03
est: -0.05 (+35.0%)
|
-0.02
est: -0.16 (+89.6%)
|
-0.04
est: -0.09 (+57.9%)
|
-0.01
est: -0.09 (+86.5%)
|
-0.02
est: -0.08 (+77.9%)
|
-0.02
est: 0.00 (-2,160.0%)
|
0.00
0.00 – 0.00
+70.2% YoY
|
0.00
0.00 – 0.00
-26.8% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-26 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-25 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-15 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-12 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Steven George Lydeamore | Chief Executive Officer | 611.9K | male |
| Flavio Palumbo | Chief Commercial Officer | 338.3K | male |
| Jerry Kanellos | Chief Operating Officer | 334.4K | — |
| Aaron Laurita | Chief Financial Officer | — | male |
| David Lyon | Head of Marketing | — | male |
| Olga Smejkalova | Company Secretary | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for IMC.AX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
